PAA is on the "UP"! So how do we maximise shareholder value AND...

PAA is on the "UP"!  So how do we maximise shareholder value AND best position the underlying SCIENCE to benefit patients?  The truth, we get bought out by a BP global player....who GENUINELY sees value in MPL, across MULTIPLE disease targets.  So we:

1) Advance as indicated the MND work into Ph2/3 later this year.

2) "Rinse and Repeat" our Ph1* MND type trial - funded by a patient community body/govt funding in Alzheimer's

We will maximise shareholder value in any engagement with BP, by showing "look it's got a real shot in MORE than just a rare disease space" ....if we can evidence, with a modest size Ph2A* trial (because we'd likely NOT have to do another Ph1) "look and here's REAL early evidence it does indeed work, in other neurological diseases"....then WOW, we've materially increased any deal BP wants to do.

It's a low [no] cost/modest time commitment way, to really make sure we lock in greater buyout value!

(Just my thoughts - NOT advice - DYOR)